ET
The startup develops small molecule inhibitors that target the endothelia receptor to reverse drug resistance in cancer patients undergoing immunotherapy. This approach aims to reduce tumor growth and extend survival in various cancers that are resistant to current immunotherapy treatments.
Updated 3 months ago
Funding
$21.1M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Features
- The startup develops small molecule inhibitors that target the endothelia receptor to reverse drug resistance in cancer patients undergoing immunotherapy. This approach aims to reduce tumor growth and extend survival in various cancers that are resistant to current immunotherapy treatments.